Format

Send to

Choose Destination
See comment in PubMed Commons below
Pathology. 2013 Feb;45(2):127-37. doi: 10.1097/PAT.0b013e32835c7645.

KIT gene mutation analysis in solid tumours: biology, clincial applications and trends in diagnostic reporting.

Author information

1
Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Abstract

Gain-of-function mutations involving c-kit protein, a cell-surface transmembrane receptor for stem cell factor, have been identified as a key oncogenic driver in a variety of solid tumours. Coupled with the development of tyrosine kinase inhibitors such as imatinib, c-kit has emerged as a viable drug target in what seems to be a validated therapeutic concept. This review will focus on gastrointestinal stromal tumours and melanomas, two types of solid tumours most closely associated with KIT gene mutations. The biology of KIT mutations in both conditions, as well as the value of KIT mutation testing in predicting disease and treatment outcomes are discussed. Since initial response to imatinib is largely influenced by mutation status, genotyping these tumours serves to facilitate personalised oncology. We also summarise our experience with diagnostic reporting of KIT mutation analysis over a period of 3 years, and briefly survey future developments in treatment, which indeed look very promising.

PMID:
23277171
DOI:
10.1097/PAT.0b013e32835c7645
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center